AbbVie Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B |
| Humira | — | $4.54B | $8.99B | $14.40B | $21.24B | $20.69B | $19.83B | $19.17B |
| Skyrizi | — | $17.56B | $11.72B | $7.76B | $5.17B | $2.94B | $1.59B | $355.0M |
| Rinvoq | — | $8.30B | $5.97B | $3.97B | $2.52B | $1.65B | $731.0M | $47.0M |
| Imbruvica | — | $2.87B | $3.35B | $3.60B | $4.57B | $5.41B | $5.31B | $4.67B |
| Venclexta | — | $2.79B | $2.58B | $2.29B | $2.01B | $1.82B | $1.34B | $792.0M |
| Botox Cosmetic | — | $2.60B | $2.72B | $2.68B | $2.62B | $2.23B | $1.11B | — |
| Botox Therapeutic | — | $3.77B | $3.28B | $2.99B | $2.72B | $2.45B | $1.39B | — |
| Juvederm Collection | — | $993.0M | $1.18B | $1.38B | $1.43B | $1.54B | $718.0M | — |
| Other Aesthetics | — | $1.27B | $1.28B | $1.23B | $1.29B | $1.47B | $760.0M | — |
| Vraylar | — | $3.62B | $3.27B | $2.76B | $2.04B | $1.73B | $951.0M | — |
| Ubrelvy | — | $1.27B | $1.01B | $815.0M | $680.0M | $552.0M | $125.0M | — |
| Qulipta | — | $1.04B | $658.0M | $408.0M | $158.0M | $0 | $0 | — |
| Vyalev | — | $482.0M | $99.0M | $3.0M | — | — | — | — |
| Other Neuroscience | — | $207.0M | $239.0M | $273.0M | $475.0M | $685.0M | $539.0M | — |
| Elahere | — | $690.0M | $479.0M | $0 | — | — | — | — |
| Epkinly | — | $271.0M | $146.0M | $31.0M | — | — | — | — |
| Other Oncology | — | $33.0M | $0 | $0 | — | — | — | — |
| Ozurdex | — | $493.0M | $494.0M | $472.0M | — | — | — | — |
| Lumigan/Ganfort | — | $410.0M | $429.0M | $432.0M | $514.0M | $579.0M | $378.0M | — |
| Alphagan/Combigan | — | $197.0M | $248.0M | $272.0M | $346.0M | $529.0M | $326.0M | — |
| Restasis | — | — | — | — | $666.0M | $1.29B | $787.0M | — |
| Other Eye Care | — | $1.01B | $1.07B | $1.24B | $1.18B | $1.17B | $693.0M | — |
| Mavyret | — | $1.32B | $1.31B | $1.43B | $1.54B | $1.71B | $1.83B | $2.89B |
| Creon | — | $1.51B | $1.38B | $1.27B | $1.28B | $1.19B | $1.11B | $1.04B |
| Linzess/Constella | — | $907.0M | $954.0M | $1.11B | $1.04B | $1.04B | $667.0M | — |
| Viekira | — | — | — | — | — | — | — | $36.0M |
| Orilissa | — | — | — | — | — | — | — | $93.0M |
| Lupron | — | — | — | — | — | — | — | $887.0M |
| Synagis | — | — | — | — | — | — | — | $718.0M |
| Synthroid | — | — | — | — | — | — | — | $786.0M |
| Kaletra | — | — | — | — | — | — | — | $283.0M |
| Sevoflurane | — | — | — | — | — | — | — | $348.0M |
| AndroGel | — | — | — | — | — | — | — | $172.0M |
| Duodopa | — | $381.0M | $447.0M | $468.0M | $458.0M | $511.0M | $494.0M | $461.0M |
| All other | — | $2.63B | $3.03B | $3.04B | $4.14B | $5.02B | $5.12B | $511.0M |
| Cost of Revenue | — | $18.20B | $16.90B | $20.42B | $17.41B | $17.45B | $15.39B | $7.44B |
| Gross Profit | — | $42.96B | $39.43B | $33.90B | $40.64B | $38.75B | $30.42B | $25.83B |
| Gross Margin | — | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% | 66.4% | 77.6% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $14.01B | $14.75B | $12.87B | $15.26B | $12.35B | $11.30B | $6.94B |
| Operating Income | — | $15.08B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B |
| Operating Margin | — | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% |
| Interest Expense | — | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B |
| Pretax Income | — | $6.60B | $3.72B | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B |
| Income Tax Expense | — | $2.36B | $-570.0M | $1.38B | $1.63B | $1.44B | $-1.22B | $544.0M |
| Net Income | — | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B |
| Net Margin | — | 6.9% | 7.6% | 9.0% | 20.4% | 20.5% | 10.1% | 23.7% |
| EPS (Basic) | — | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 |
| EPS (Diluted) | — | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 |
| Shares Outstanding (Basic) | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.67B | 1.48B |
| Shares Outstanding (Diluted) | 1.77B | 1.77B | 1.77B | 1.77B | 1.78B | 1.78B | 1.67B | 1.48B |
| Dividends Per Share | — | $6.65 | $6.29 | $5.99 | $5.71 | $5.31 | $4.84 | $4.39 |